A novel QSAR model for designing, evaluating, and predicting the antiMES activity of new 1H-pyrazole-5-carboxylic acid derivatives

Abstract

A quantitative structure–activity relationship (QSAR) study was performed to develop a model that relates the structures of 62 compounds, which have activity against maximal electroshock induced seizure (MES), with their anti-MES activity. Molecular structures of the compounds were geometrically optimized and energetically minimized using a combination of modified Merck force field (MMFF) molecular mechanics, Austin model 1 (AM1) semi-empirical quantum mechanical and density functional theory (DFT) quantum mechanical method using the Becke’s three parameter exchange functional (B3) hybrid with Lee, Yang and Parr correlation functional (LYP) and basis set of the double zeta split valence plus polarization quality 6-31G** i.e. B3LYP/6-31G**. Theoretically derived descriptors were obtained from the optimized structures, a genetic function approximation (GFA) algorithm was also applied to select the optimal descriptors and multiple linear regression (MLR) was used to establish a relationship between the anti-MES activity of the compounds and the optimal molecular descriptors. A six-parametric equation containing dipole moment (μ), energy of the lowest unoccupied molecular orbital (ϵLUMO), polar surface area (PSA), accessible surface area derived from wave function (WAA), sum of the square root of square of the charge on all atom of the molecule (QA) and sum of the square root of square of the charge on all fluorine atom in the molecule was obtained as the QSAR model in the present study with good statistical qualities (R²=0.937, R²_adj=0.928, F=104.11, R²_pred=0.929 and  Q²=0.913). The QSAR model was used to study estimate the anti-MES activities of 1H-pyrazole-5-carboxylic acid derivatives not yet synthesized. 10 out of the 101 screened compounds had improved anti-MES activity when compared to the template (i.e. ethyl 4-(4-chlorophenyl)-3-morpholino-1H-pyrrole-2-carboxylate, which is compound number 61 in the dataset) used to design the 101 derivatives. These 10 compounds were docked with voltage-gated sodium channel (PDB code: 2KaV) and there binding affinity were found to were found to be comparable to that of phenytoin (a standard drug known to possess anti-MES activity).

Keywords

• : MES
• QSAR
• GFA
• Molecular docking
• Kennard-Stone algorithm

References

1. 1. McCormick D A, Contreras D. On the cellular and network bases of epileptic seizures Annu. Rev. Physiol. 2001 March; 63: 815-846. DOI: 10.1146/annurev.physiol.63.1.815
2. 2. Bohdan MM. Seizures-what is the mechanism underlying clinical manifestation of seizure activity as seen in epilepsy? American college of emerging physicians’ news. 2007 http://www.acep.org/clinical-practice Retrieved on December 2nd 2016 at 4.03 am.
3. 3. Gavernet L, Barrios IA, Sella CM, Bruno-Blanch LE. Design, synthesis, and anticonvulsant activity of some sulfamides. Bioorganic & Medicinal Chemistry. 2007; 15:5604–5614. http://dx.doi.org/10.1016/j.bmc.2007.05.024.
4. 4. Estrada E, Pena A. In Silico studies for the rational discovery of anticonvulsant compounds. Bioorg. Med.Chem. 2000 December; 8:2755- 2770. DOI: 10.1016/S0968-0896(00)00204-2.
5. 5. Reijs R, Aldenkamp AP, De Krom M. Mood effects of antiepilepsy drug. Epilepsy Behav. 2004 Febuary; 5(1):66-76. DOI: http://dx.doi.org/10.1016/j.yebeh.2003.11.009
6. 6. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004 September- October; 61(1-3) 1-48. DOI: 10.1016/j.eplepsyres.2004.07.010
7. 7. Edafiogho IO, Ananthalakshmi KV, Kombian SB. Anticonvulsant evaluation and mechanism of action of benzylamino enaminones. Bioorg. Med. Chem. 2006 March 14(150):15566-5272. Dio:10.1016/j.bmc.2006.03.049
8. 8. Eddington ND, Cox DS, Khurana M, Salama NN, Stables JP, Harrison SJ, Negussie A, Taylor RS, Tran UQ, Moore JA. Synthesis and anticonvulsant activity of enaminones. Part 7. Synthesis and anticonvulsant evaluation of ethyl 4-[(substituted phenyl)amino]-6-methyl-2-oxocyclohex-3-ene-1-carboxylates and their corresponding 5-methylcyclohex-2-enone derivatives. Eur J Med Chem. 2003 March; 38: 49–64. Doi:10.1016/S0223-5234(02)00006-5

9. 9. Malawska B, Kulig K, S’Piewaka A, Stables J. Investigation into new anticonvulsant derivatives of α-substituted N-benzylamides of γ-hydroxy- and γ-acetoxybutyric acid. Part5. Search for new anticonvulsant compounds. Bioorg Med Chem. 2004 Febuary; 12: 625-632. DOI: 10.1016/j.bmc.2003.10.036 10. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999; 40 (Suppl.): S2-10. https://www.ncbi.nlm.nih.gov/pubmed/ 10530688
10. 11. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 1990 September; 42: 223-286. http://pharmrev.aspetjournals.org/content/42/3/223.long
11. 12. Leppik IE. Antiepileptic drugs in development: prospects for the near future. Epilepsia 1994 August, 35, 29-40. DOI: 10.1111/j.1528-1157.1994.tb05953.
12. 13. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages Br. J. Clin. Pharmacol. 1996 November; 42: 531-543. DOI: 10.1111/j.1365-2125.1996.tb00107.x
13. 14. Loscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 1994, 17(2): 95-134. https://www.ncbi.nlm.nih.gov/pubmed/8194514
14. 15. Ibezim EC, Duchowicz PR, Ibezim NE, Mullen LMA, Onyishi IV, Brown SA, Castro EA. Computer - aided linear modeling employing QSAR for drug discovery. Scientific Research and Essay. 2009 December;4(13):1559-1564.http://www.idosi.org/abjas/abjas1(3-4)09/7pdf
15. 16. Cox B, Nobbs MS, Shah GP, Edney DD, Loft MS. Pyrazine compounds- Patent WO9838174. Exp.Opin.Ther.Patents. 1999; 9(10):1431-1436 http://dx.doi.org/10.1517/13543776.9.10.1431
16. 17. Bhutoria S, Ghoshal N. A Novel Approach for the Identification of Selective Anticonvulsants Based on Differential Molecular Properties for TBPS Displacement and Anticonvulsant Activity: An Integrated QSAR Modelling, QSAR Comb. Sci. 2008 May; 27(7): 876 – 889. DOI: 10.1002/qsar.20086000
17. 18. Macchiarulo A, De luca L, Costantino et al. QSAR study of anticonvulsant negative allosteric modulator of the AMPA receptor. J med. chem. 2004 March; 47:1860-1863. doi/abs/10.1021/jm0310838
18. 19. Abdulfatai U, Uzairu A, Uba S. Quantitative structure activity relationship study of anticonvulsant activity of α_substituted acetamido-N-benzylacetamide derivatives, Cogent Chemistry. 2016 April ;(2):1-12. http://dx.doi.org/10.1080/23312009.2016.1166538
19. 20. Lesk AM. Introduction to bioinformatics. Oxford University Press; 2002. 207p. ISBN: (pbk)0199251967
20. 21. Pedro JB, John BOM. A machine learning approach to predicting protein–ligand binding affinity with applications to molecular docking. Bioinformatics. 2010 May; 26(9): 1169-1175. doi:10.1093/bioinformatics/btq112
21. 22. Kornet MJ, Chu JYR. Synthesis and anticonvulsant testing of 4-phenylsemicarbazides J. Pharm. Sci. 1983 October; 72:1213-1215. DOI: 10.1002/chin.198414170
22. 23. Pajouhesh H, Parson R, Popp FD. Potential Anticonvulsants VI: Condensation of Isatins with Cyclohexanone and other Cyclic Ketones. J. Pharm. Sci. 1983 March; 72:318-321. doi: 10.1002/jps.2600720330
23. 24. Popp, F. D.; Pajouhesh, H. Potential anticonvulsants IV: Condensation of isatin with benzoylacetone and isopropyl methyl ketone. J. Pharm. Sci. 1982 September;71:1052-1054. DOI: http://dx.doi.org/10.1002/jps.2600710924
24. 25. Haj-Yehia A, Bialer M. Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J. Pharm. Sci. 1990 August, 79, 719-724.DOI: http://dx.doi.org/10.1002/jps.2600790814
25. 26. Hernandez-Gallegos Z, Lebmann PA. Partition Coefficients of three new anticonvulsants. J. Pharm. Sci. 1990 November; 79:1032-1033.DOI : http://dx.doi.org/10.1002/jps.2600791118
26. 27. Crider AM, Kolczynski TM, Miskell DL. Synthesis and anticonvulsant activity of racemic 2-amino-N-substituted succinimide derivatives. J. Pharm. Sci. 1981 Febuary, 70:192-195. DOI: http://dx.doi.org/10.1002/jps.2600700220
27. 28. Darling CM, Pryor P. Anticonvulsant activity of alkyl-substituted N-benzylcyanoacetamides J. Pharm. Sci. 1979 January; 68, 108-110. DOI:10.1002/jps.2600680137
28. 29. Kelley JL, Linn JA, Bankston DD, Burchall CJ, Soroko FE, Cooper BR. 8-Amino-3-benzyl-1,2,4-triazolo[4,3-a]pyrazines. Synthesis and anticonvulsant activity. J. Med. Chem. 1995 September; 38: 3676-3679.DOI: 10.1021/jm00018a029
29. 30. Kelley JL, Davis RG, McLean EW, Glen RC, Soroko FE, Cooper BR. Synthesis and anticonvulsant activity of N-Benzylpyrrolo[2,3-d]-, -pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: imidazole ring-modified analogs of 9-(2-Fluorobenzyl)-6-(methylamino)-9H-purine. J. Med. Chem.1995 September; 38 (19): 3884–3888.DOI: 10.1021/jm00019a019
30. 31. Kelley JL, Koble CS, Davis RG, McLean EW, Soroko FE, Cooper BR. l-(Fluorobenzyl)-4-amino-1H 1,2,3-triazolo[4,5-c]pyridines:Synthesis and Anticonvulsant ActivityJ. Med. Chem. 1995 September;38 (20): 4131–4134. DOI: 10.1021/jm00020a030 32. Dimmock JR, Puthucode RN, Smith JM, Hetherington M, Quail JW, Pugazhenthi U, Lechier T, Stables JP.(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. J Med Chem. 1996 September; 39(20):3984-97. DOI:10.1021/jm9603025
31. 33. Puthucode RN, Pugazhenthi U, Quail JW, Stables JP, Dimmock JR. Anticonvulsant activity of various aryl, arylidene and aryloxyaryl semicarbazones Eur. J. Med. Chem. 1998 July-August; 33: 595-607. http://dx.doi.org/10.1016/S0223-5234(98)80018-4
32. 34. Unverferth K, Engel J, Hofgen N, Rostock A, Gunther R, Lankau HJ, Menzer M, Rolfs A, Liebscher J, Mu¨ ller B, et al. Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel blocking 3-aminopyrroles. J Med Chem.1998 January; 41:63–73. DOI: 10.1021/jm970327j
33. 35. Shao Y, Molnar LF, Jung Y, Kussmann J, Ochsenfeld C, Brown ST, Gilbert ATB, Slipchenko LV, Levchenko SV, O’Neill DP, DiStasio RA, Lochan RC, Wang T, Beran GJO, Besley NA, Herbert JM, Lin CY, Van Voorhis T, Chien SH, Sodt A, Steele RP, Rassolov VA, Maslen PE, Korambath PP, Adamson RD, Austin B, Baker J, Byrd EFC, Dachsel H, Doerksen RH, Dreuw A, Dunietz BD, Dutoi AD, Furlani TR, Gwaltney SR, Heyden A, Hirata S, Hsu CP, Kedziora G, Khalliulin RZ, Klunzinger P, Lee AM, Lee MS, Liang WZ, Lotan I, Nair N, Peters B, Proynov EI, Pieniazek PA, Rhee YM, Ritchie J, Rosta E, Sherril CD, Simmonett AC, Subotnik JE, Woodcock III HL, Zhang W, Bell AT, Chakraborty AK, Chipman DM, Keil FJ, Warshel A, Hehre WJ, Schaefer HF, Kong J, Krylov AI, Gill PMW, Head-Gordon M. Advances in methods and algorithms in modern quantum chemistry program package. Phys. Chem. Chem. Phys., 2006 June; 8, 3172. DOI: 10.1039/B517914A
34. 36. Singh P. Quantitative structure-activity relationship study of substituted-[1,2,4] oxadiazoles as S1P1 agonists. Journal of Current Chemical and Pharmaceutical Sciences. 2013 Febuary; 3(1), .64-67. www.sadgurupublications.com/ContentPaper/2013/9192JCCPS3(1)2013P.pdf
35. 37. Ambur P, Aher RB, Gajewicz A, Pyzyt WRK, “NanoBRIDGES” software:open acess tools to perform QSAR and nano-QSAR modeling. Chem. Intel. Lab. Syst, 2015 Octomber; 147, 1-13. http://dx.doi.org/10.1016/j.chemolab.2015.07.007
36. 38. Kennard RW, Stone LA. Computer aided design of experiments. Technometrics. 1969 Febuary; 11:137–148. doi:10.2307/1266770
37. 39. Melagraki G, Afantitis A, Makridima K, Sarimveis H, Igglessi- Markopoulou O. Prediction of toxicity using a novel RBF neural network training methodology. J Mol Model. 2006 Febuary; 12:297–305. doi:10.1007/s00894-005-0032-8
38. 40. Afantitis A, Melagraki G, Sarimveis H, Koutentis PA, Markopoulos J, Igglessi-Markopoulou O. A novel QSAR model forpredicting induction of apoptosis by 4-aryl-4H-chromenes. Bioorg Med Chem. 2006 May; 14:6686–6694. doi:10.1016/j.bmc.2006.05.061
39. 41. Chakraborti AK, Gopalakrishnan B, Sobhia ME, Malde A. 3D-QSAR studies of indole derivatives as phosphodiesterase IV inhibitors. Eur J Med Chem. 2003 September; 38:975–982. doi:10.1016/j.ejmech. 2003.09.001
40. 42. Wu W, Walczak B, Massart DL,Heuerding S, Erni F, Last IR, Prebble KA. Artificial neural networks in classification of NIR spectral data: design of the training set. Chemom Intell Lab Syst. 1996 May; 33:35–46. doi:10.1016/0169-7439(95)00077-1
41. 43. Material studio 7.0 modeling and simulation software. Accerlys software Inc. 2007 available online at http//:accerlys.com/product/
42. 44. Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J.Chem. Inf. Comp. Sci.1994 July; 34, 854-866. DOI: 10.1021/ci00020a020
43. 45. Allison PD. Multiple regression: a primer. London: Pine Forge Press; 1999. 10-147p. ISBN-10: 0761985336
44. 46. Larose TD. Data mining methods and models. Wiley Interscience; 2002.114p. ISBN-13 978-0-471-66656-1.
45. 47. Golbraikh A, Tropsha A. Beware of q2!. J Mol Graphics Mod 2002 January; 20, 269–276. http://dx.doi.org/10.1016/S1093-3263(01)00123-1
46. 48. Roy K, Mitra I, Kar S, Ojha PK, Das RN, Kabir H. Comparative studies on some metrics for external validation of QSPR models. J Chem Inf Model. 2012 Febuary; 52:396–408. DOI:10.1021/ci200520g
47. 49. Tropsha A, Gramatica P, Gombar VK. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci. 2003 Apil; 22:69–77. doi:10.1002/qsar.200390007
48. 50. Minovski N, Zuperl S, Drgan V, Novi M. Assessment of applicability domain for multivariate counter-propagation artificial neural network predictive models by minimum Euclidean distance space analysis: A case study. Analytica Chimica Acta. 2013 January;759:28–42. DOI: 10.1016/j.aca.2012.11.002
49. 51. Netzeva TI, Worth AP, Aldenberg T, Benigni R, Cronin MTD, Gramatica P, Jaworska JS, Kahn S, Klopman G, Marchant CA, Myatt G, Nikolova-Jeliazkova N, Patlewicz GY, Perkins R, Roberts DW, Schultz TW, Stanton DT, Van De Sandt JJM, Tong W, Veith G, Yang C. Current status of methods for defining the applicability domain of (quantitative) structure–activity relationships. Altern. Lab. Anim. 2005 April; 33, 155–173. http://www.atla.org.uk/current-status
50. 52. Topliss JG, Costello RJ. Chance correlations in structure– activity studies using multiple regression analysis. J Med Chem. 1972 Octomber; 15, 1066–1068 DOI: 10.1021/jm00280a017
51. 53. Motta LF, Gaudio AC, Takahata Y. Quantitative Structure–Activity Relationships of a Series of Chalcone Derivatives (1,3–Diphenyl–2–propen–1–one) as Anti Plasmodium falciparum Agents (Anti Malaria Agents), Internet Electron. J. Mol. Des. 2006, 5, 555–569, http://www.biochempress.com.
52. 54. David AB, Edwin K, Roy EW. Regression diagnostics: indentifying influential data and source of collinearity. Wiley-interscience: John Wiley & Sons, lnc., Hoboken, New Jersey, 2004. 85-93p. ISBN 0-47 1-69 1 17-8
53. 55. Ibezim EC, Duchowicz PR, Ibezim NE, Mullen LMA, Onyishi IV, Brown SA, Castro EA. Computer-Aided Linear Modeling Employing Qsar for Drug Discovery. African Journal of Basic and Applied Sciences. 2006; 1 (3-4), 76-82. https://www.idosi.org/ajbas/ajbas1(3-4)09/7.pdf
54. 56. Shapiro S, Guggenheim B. Inhibition of oral bacteria by phenolic compounds. Part 1 QSAR analysis using molecular connectivity. Quant. Struct.-Act. Relat. 1998 August; 17, 327–33. DOI: 10.1002/(SICI)1521-3838(199808)17:04<327::AID-QSAR327>3.0.CO;2-O
55. 57. Noolvi MN, Patel HM, Bhardwaj V. 2D qsar studies on a series of 4-anilino quinazoline derivatives as tyrosine kinase (egfr) inhibitor: an approach to design anticancer agents. Digest Journal of Nonmaterial and Biostructures. 2010 April; 5(20):387–401. http/:www.researchgate.net/262187015
56. 58. Habibi-Yangjeh A, Danandeh-Jenagharad M. Application of a genetic algorithm and an artificial neural network for global prediction of the toxicity of phenols to Tetrahymena pyriformis. Monatsh Chemistry 2009 October; 140, 1279–1288. doi: 10.1007/s00706-009-0185-8
57. 59. Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inf. 2010 July; 29, 476–488. DOI: 10.1002/minf.201000061
58. 60. Warren H, Sean O. Spartan 14 for windows, machintosh and linux tutorial and user's Guide. 18401 Von Karman Avenue, Suite 370 Irvine, CA 92612 U.S.A: Wavefunction Incoorperated; 2014. 289-291p. ISBN: 978-1-890661-42-2
59. 61. Stenberg P, Luthman K, Ellens H, Lee CP, Smith PL, Lago A, Elliot JD, Artursson P. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharm. Res. 1999 Octomber; 16:1520–1526. doi:10.1023/A:1015092201811
60. 62. Clark, DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 1999 August; 88:807–816. DOI:10.1021/js980402t
61. 63. Franke, R. Theoretical Drug Design Methods. Elsevier: Amsterdam. 1984.115-123p.
62. 64. Osmialowski K, Halkiewicz J, Radecki A, Kaliszan, R. Quantum chemical parameters in correlation analysis of gas liquid chromatographic retention indices of amines J. Chromatography. 1985 December, 346, 53-60. DOI: 10.1016/S0021-9673(00)90493-X
63. 65. Fleming, I. Frontier Orbitals and Organic Chemical Reactions. Somerset New Jersey: John Wiley and Sons; 1976. 308p. ISBN 10: 0471018198
64. 66. Todeschini R, Consonni V, Mannhold R. Handbook of molecular descriptors. Wiley-VCH, Weinheim; 2000. 1-688p. ISBN 3-52-29913-0
65. 67. Cartier A, Rivail, JL. Electronic Descriptors in Quantitative Structure-Activity Relationship. Chemom. Intell. Lab. Sys. 1987 October, 1, 335-347. DOI: 10.1016/0169-7439(87)80039-4
66. 68. Bodor N, Gabanyi Z, Wong CK. A new method for the estimation of partition coefficient J. Am. Chem. Soc. 1989 May; 111: 3783-3786. DOI: 10.1021/ja00193a003
67. 69. Buydens L, Massart D, Geerlings P. Prediction of gas chromatographic retention indexes with topological, physicochemical, and quantum chemical parameters Anal. Chem. 1983 April, 55, 738-744. DOI: 10.1021/ac00255a034
68. 70. Klopman G, Iroff LD. Calculation of partition coefficients by the charge density method. J. Comput. Chem. 1981 June; 2: 157-160 DOI: 10.1002/jcc.540020204
69. 71. Ruslin N, Syamsudin. Quantitative Structure-Activity Relationship Analysis of Antimalarial Compound of Mangostin Derivatives Using Regression Linear Approach. Asian Journal of Chemistry. 2013 September; 25(11): 6136-6140. https://www.researchgate.net/.../260600323
70. 72. Clare, B. W.; Supuran, C. T. Carbonic anhydrase activators. 3: structure-activity correlations for a series of isozyme II activators. J. Pharm. Sci. 1994 June; 83:768. DOI: http://dx.doi.org/10.1002/jps.2600830603
71. 73. Ordorica MAV, Velázquez MLM, Ordorica JGV, Escobar JLV, Lehmann PAF. A Principal Component and Cluster Significance Analysis of the Antiparasitic Potency of Praziquantel and some Analogues. Quant. Struct.-Act. Relat. 1993; 12: 246–250. doi:10.1002/qsar.19930120305
72. 74. Milouser VZ, Leven JA, Arbing MA, Hunt JF, Put GS, Palmer AG. Solution structure of the NaV1.2 C-terminal EF-hand domain. J boil chemistry. 2009; 284: 6646-6654. DOI: 10.1074/jbc.M807401200
73. 75. Discovery studio visualization tool and modeling environment, BIOVIA discovery studio 2016 client: Accerlys software Inc. avilalable online at accelrys.com/resource-center/.../updates/discovery-studio/dstudio2016/latest.htm
74. 76. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading, Journal of Computational Chemistry. 2010 January; 31: 455-461 Doi 10.1002/jcc-21334.